Spectrum Pharmaceuticals

Spectrum Pharmaceuticals Net Margin

Delisted

The Net Profit Margin of Spectrum Pharmaceuticals (SPPI) as of Nov 15, 2026 is -772.24 %. In the previous year, Net Profit Margin was -268.54 M % — a change of -100.00% (higher).

Net Margin

-772.24 %

YoY

-100.00%

Last updated:

Net Profit Margin of Spectrum Pharmaceuticals is 2022 -772.24 % . Net Profit Margin of Spectrum Pharmaceuticals was 2021 -268.54 M % . It decreases by -100.00% higher compared to the previous year.

Spectrum Pharmaceuticals's net margin stands at -772.2%, down from -109.8% several years earlier.

The Spectrum Pharmaceuticals Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2015
-31.24 USD
Jan 1, 2016
-46.78 USD
Jan 1, 2017
-71.08 USD
Jan 1, 2018
-109.77 USD
Jan 1, 2019
-598.66 USD
Jan 1, 2020
-1.61 M USD
Jan 1, 2021
-268.54 M USD
Jan 1, 2022
-772.24 USD
The Spectrum Pharmaceuticals Net Margin history
YEARNet MarginYoY
-772.24 %-100.00%
-268.54 M %+16,626.25%
-1.61 M %+268,079.88%
-598.66 %+445.39%
-109.77 %+54.42%
-71.08 %+51.94%
-46.78 %+49.75%
-31.24 %+27.67%
-24.47 %+6,038.17%
-0.40 %-212.88%
0.35 %+40.46%
0.25 %-138.15%
-0.66 %+31.58%
-0.50 %-6.98%
-0.54 %-87.86%
-4.44 %+8.09%
-4.10 %-87.30%
-32.31 %-32.15%
-47.62 %+358.33%
-10.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Spectrum Pharmaceuticals Stock analysis

What does Spectrum Pharmaceuticals do? Spectrum Pharmaceuticals Inc. is an American biotechnology company specializing in the development and commercialization of drugs for the treatment of cancer and other serious diseases. It was founded in 1987 and is headquartered in Irvine, California. The company's CEO is Rajesh C. Shrotriya, who has a clear vision of specializing in pharmaceutical development to meet the needs of patients with unmet medical needs. Spectrum Pharmaceuticals has a wide range of products, with a focus on oncology and hematology. It also has a promising drug candidate pipeline. The company works closely with healthcare professionals and regulatory authorities to ensure the highest quality standards are met. Spectrum Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Spectrum Pharmaceuticals stock

Net Profit Margin of Spectrum Pharmaceuticals is -772.24 % in 2022.

Net Profit Margin of Spectrum Pharmaceuticals changed from -268.54 M % to -772.24 %, representing a -100.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Spectrum Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Spectrum Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Spectrum Pharmaceuticals

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Spectrum Pharmaceuticals